[Skip to Content]
[Skip to Content Landing]
Correspondence
November 17, 2008

Scarring Alopecia Associated With Use of the Epidermal Growth Factor Receptor Inhibitor Gefitinib

Author Affiliations
 

Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2008

Arch Dermatol. 2008;144(11):1524-1525. doi:10.1001/archderm.144.11.1524

Follicular eruptions are well-recognized adverse effects of epidermal growth factor receptor (EGFR) inhibitor therapy.1 Although alopecia is uncommon, mice with targeted disruption of the EGFR develop alopecia.2,3 We report the development of scarring alopecia associated with use of the EGFR inhibitor gefitinib (Iressa; AstraZeneca, Mississisauga, Ontario, Canada).

×